Skip to main content


Freshfields advises MicroPort Scientific on its acquisition of Hemovent GmbH

Freshfields Bruckhaus Deringer (‘Freshfields’) has advised Hong Kong-listed and Shanghai-based MicroPort Scientific Corporation on the acquisition of 100 per cent of the capital of Hemovent GmbH, Aachen, previously held by the founders and growth capital investors. Hemovent is primarily active in the development and production of mobile heart-lung machines (so-called ECMO devices). The acquisition has been approved by the German Federal Ministry for Economic Affairs and Energy without commitments and is expected to close in due course.

MicroPort has established itself in the critical care sector with its subsidiary MicroPort Surgery, which is committed to providing patients with comprehensive medical solutions for cardiac surgery, emergency and critical care. With the acquisition of Hemovent, MicroPort will further enhance its strategy in emergency and critical care by combining cardiopulmonary bypass (CPB) with research and development, manufacturing and marketing of ECMO products.

The Freshfields team included partners Heiner Braun (Corporate) and Frank Röhling (Antitrust and Trade), Counsel Sascha Arnold (Regulatory), as well as Friedrich von der Heydt, Panagiota Kavvada, Marius Scherb, Philipp Lehmann, Till Burmeister (all Corporate), Marie-Theres Urban, Lara Steinbach (both Antitrust and Trade), Florian Oppel (Tax), Hendrik Bier (People and Reward) and Katharina Reinhardt (Regulatory).